Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interactions between SARS coronavirus 2 papain‐like protease and immune system: A potential drug target for the treatment of COVID‐19
Shahab Mahmoudvand, Somayeh Shokri
Scandinavian Journal of Immunology (2021) Vol. 94, Iss. 4
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
Sven Ullrich, Kasuni B. Ekanayake, Gottfried Otting, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 62, pp. 128629-128629
Open Access | Times Cited: 181
Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin
Paweł M. Wydorski, J. Osipiuk, Benjamin T. Lanham, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 50
SARS‐CoV‐2 Papain‐Like Protease: Structure, Function and Inhibition
Sven Ullrich, Christoph Nitsche
ChemBioChem (2022) Vol. 23, Iss. 19
Open Access | Times Cited: 43
Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen
Alice Mac Kain, Ghizlane Maarifi, Sophie‐Marie Aicher, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 39
Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro
Devin S. M. Lewis, Joanna Ho, Savannah Wills, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 32
Pharmacotherapeutic Potential of Natural Products to Target the SARS-CoV-2 PLpro Using Molecular Screening and Simulation Approaches
Abrar Mohammad Sayaf, Hassaan Ahmad, Muhammad Ammar Aslam, et al.
Applied Biochemistry and Biotechnology (2023) Vol. 195, Iss. 11, pp. 6959-6978
Open Access | Times Cited: 15
9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2
Kabita Pandey, Devin S. M. Lewis, Kyun Heo, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The Dual Role of cGAS-STING Signaling in COVID-19: Implications for Therapy
Daniele Castro di Flora, Jenny Lara, Aline Dionízio, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 362-362
Open Access
Aurasperone A Inhibits SARS CoV-2 In Vitro: An Integrated In Vitro and In Silico Study
Mai H. ElNaggar, Ghada Mahmoud Abdelwahab, Omnia Kutkat, et al.
Marine Drugs (2022) Vol. 20, Iss. 3, pp. 179-179
Open Access | Times Cited: 19
The substrate selectivity of papain-like proteases from human-infecting coronaviruses correlates with innate immune suppression
Yuxian Xiong, Bin Huang, Ying Yang, et al.
Science Signaling (2023) Vol. 16, Iss. 783
Open Access | Times Cited: 12
Targeting papain-like protease by natural products as novel therapeutic potential SARS-CoV-2
Muhammad Waqas, Saeed Ullah, Sobia Ahsan Halim, et al.
International Journal of Biological Macromolecules (2023) Vol. 258, pp. 128812-128812
Closed Access | Times Cited: 9
SARS-CoV-2 and UPS with potentials for therapeutic interventions
Jannatul Ferdoush, Rizwaan Abdul Kadir, Selin Simay Kaplanoglu, et al.
Gene (2024) Vol. 912, pp. 148377-148377
Closed Access | Times Cited: 3
A computational essential dynamics approach to investigate structural influences of ligand binding on Papain like protease from SARS-CoV-2
Ekampreet Singh, Rajat Kumar Jha, Rameez Jabeer Khan, et al.
Computational Biology and Chemistry (2022) Vol. 99, pp. 107721-107721
Open Access | Times Cited: 15
Targeting the cGAS-STING pathway as an inflammatory crossroad in coronavirus disease 2019 (COVID-19)
Reza Elahi, Salar Hozhabri, Amirhosein Moradi, et al.
Immunopharmacology and Immunotoxicology (2023) Vol. 45, Iss. 6, pp. 639-649
Closed Access | Times Cited: 8
Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure–activity relationships
Lukáš Kerti, Vladimı́r Frecer
Bioorganic & Medicinal Chemistry (2024), pp. 117909-117909
Open Access | Times Cited: 2
Mechanistic Insights into Targeting SARS-CoV-2 Papain-like Protease in the Evolution and Management of COVID-19
Nonjabulo Ntombikhona Magwaza, Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, et al.
BioChem (2024) Vol. 4, Iss. 3, pp. 268-299
Open Access | Times Cited: 2
Long noncoding RNAs in respiratory viruses: A review
Mina Mobini Kesheh, Shahab Mahmoudvand, Somayeh Shokri
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 16
Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study
Shambo Samrat Samajdar, Shatavisa Mukherjee, Saibal Moitra, et al.
Lung India (2023) Vol. 40, Iss. 2, pp. 107-111
Open Access | Times Cited: 6
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)
Sven Ullrich, Kasuni B. Ekanayake, Gottfried Otting, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 14
Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease
Huarui Qiao, Lingyun Li, Lu Wang, et al.
Protein Expression and Purification (2023) Vol. 207, pp. 106267-106267
Open Access | Times Cited: 5
Preferability of Molnupiravir, an Anti-COVID-19 Drug, toward Purine Nucleosides: A Quantum Mechanical Study
Mahmoud A. A. Ibrahim, Mohammed N. I. Shehata, Nayra A. M. Moussa, et al.
ACS Omega (2023) Vol. 8, Iss. 30, pp. 27553-27565
Open Access | Times Cited: 5
Predicting human and viral protein variants affecting COVID-19 susceptibility and repurposing therapeutics
Vaishali Waman, Paul Ashford, Su Datt Lam, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Circular RNAs as emerging regulators in COVID-19 pathogenesis and progression
Xiaojun Gao, Dan Fang, Yulong Liang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity
Anasha Kawall, Devin S. M. Lewis, Avini Sharma, et al.
Frontiers in Chemistry (2023) Vol. 10
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top